Clinical trials: Radiocontrast Nephropathy
Radiocontrast Nephropathy
N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients
Multiple agents have been studied to prevent radiocontrast nephropathy. One of these agents is N-Acetylcysteine. Previous trials to assess N-Acetylcysteine's efficacy in the prevention of contrast nephropathy have been promising.
- Trial name
- NCT00780962
- Testing
- N-Acetylcysteine (NAC), 0.9% Sodium-chloride
- Where
- United States
- Volunteers
- 399 people
- Sponsor
- Beth Israel Deaconess Medical Center
Radiocontrast-induced Nephropathy
Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material
Millions of people receive radiographic contrast material for investigations like CT and coronary angiography. While considered safe in healthy patients, it can cause acute renal impairment.
- Trial name
- NCT00558142
- Testing
- Acetylcysteine, Visipaque 320
- Where
- United Kingdom
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh